We select targets with clear opportunity for a precision medicine strategy to address three target categories in what we consider “therapeutic white spaces” of underserved populations.
Validated oncogene targets
Novel cancer targets
Mut-Sel EGFR Exon 20 insertion
Mut-Sel EGFR Exon 19 deletion / Exon 21 mutation
Best-in-class Discovery Programs Against Validated Targets
First-in-Class Discovery Programs Against Undruggable Targets
First-in-Class Discovery Programs Against Novel Cancer Targets